TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
Appointment builds on CHF 10 million seed financing and Board leadership expansion
Basel, Switzerland, January 29, 2026 – TECregen, a biotechnology company pioneering thymus rejuvenation, today announced the appointment of Dr. Klaas P. Zuideveld, Ph.D., as Chief Executive Officer (CEO). Dr. Zuideveld will lead TECregen’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience.
